Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.

MLA

Lofiego, Maria Fortunata, et al. “Epigenetic Remodeling to Improve the Efficacy of Immunotherapy in Human Glioblastoma: Pre-Clinical Evidence for Development of New Immunotherapy Approaches.” Journal of Translational Medicine, vol. 22, no. 1, Mar. 2024, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s12967-024-05040-x.

APA

Lofiego, M. F., Piazzini, F., Caruso, F. P., Marzani, F., Solmonese, L., Bello, E., Celesti, F., Costa, M. C., Noviello, T., Mortarini, R., Anichini, A., Ceccarelli, M., Coral, S., Di Giacomo, A. M., Maio, M., & Covre, A. (2024). Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches. Journal of Translational Medicine, 22(1), 1–13. https://doi.org/10.1186/s12967-024-05040-x

Chicago

Lofiego, Maria Fortunata, Francesca Piazzini, Francesca Pia Caruso, Francesco Marzani, Laura Solmonese, Emma Bello, Fabrizio Celesti, et al. 2024. “Epigenetic Remodeling to Improve the Efficacy of Immunotherapy in Human Glioblastoma: Pre-Clinical Evidence for Development of New Immunotherapy Approaches.” Journal of Translational Medicine 22 (1): 1–13. doi:10.1186/s12967-024-05040-x.